NHS Blood Test for Inherited Disorders Rolls Out, Aiming to Minimize Transfusion Side-Effects

Starting today, thousands of individuals in England living with inherited blood disorders, including sickle cell disorder and thalassaemia, will have access to an unprecedented 'blood matching' genetic test. The groundbreaking service, offered by the NHS, aims to minimize the risk of side effects and deliver more personalized care to these patients.

How Does the Genetic Blood Test Work?

By conducting a DNA analysis of patients' blood groups, this innovative test allows for more accurate matching for those in need of transfusions. This is especially crucial for those with complex requirements. Concurrently, donor blood is also examined in a similar program. Blood group genotyping can, therefore, greatly facilitate finding suitable blood matches for patients.

The Need for Better Blood Matching

• Blood transfusions create life-saving solutions for those with rare inherited blood disorders, but about one in five patients develops antibodies against certain blood groups after receiving a transfusion. This subsequent development may cause treatment delays due to the difficulty in finding matching blood or potential reactions to blood transfusion.
• Approximately 17,000 individuals in England live with sickle cell disorder, an inherited disease resulting in damaged red blood cells that can cause organ damage and severe pain.
• Thalassaemia, another inherited blood disorder, affects the bodys ability to produce sufficient haemoglobin leading to severe anaemia. It mainly affects those of Asian, Middle Eastern, Southern Mediterranean heritage with roughly 800 patients in England.

To mitigate these complications, NHS is encouraging patients with these conditions to take the test as part of their routine hospital blood tests.

The Impact of the Test on Patients with Inherited Blood Disorders

Patient Ama Aryee, a 34-year-old science teacher who has sickle cell disorder, shared her experiences and the trials of finding matching blood due to antibodies acquired after emergency blood transfusions. Her story emphasizes the importance of the new testing system and the need for this life-changing technology. Hunting for compatible blood is now less cumbersome with the advent of this test.

Moving Forwards with the Test

Health professionals and authorities welcome this advancement and expect a compelling improvement in the treatment of patients with inherited blood disorders. Health Minister Andrea Leadsom expressed enthusiasm about the leap forward this represents for those living with these conditions. She said, 'This is another example of the NHS leading the way in healthcare.'

Patient Advocacy Groups React

Public reactions to the news have been overwhelmingly positive, with advocacy groups praising the directive. John James, Chief Executive of the Sickle Cell Society, commended this tremendous stride for better blood matches for everyone living with the disorder. Echoing his sentiments, Roanna Maharaj of the UK Thalassaemia Society, also voiced support.